Biotechnology cancer Cancer screening

Organ-sparing treatments effective for bladder cancer; Brachytherapy cost-effective treatment for prostate cancer

Traditionally, treatment for muscle-invasive bladder cancer is chemotherapy followed by the removal of the patient’s entire bladder, known as a radical cystectomy. However, Beaumont researchers have data suggesting that treatment consisting of limited surgery followed by combination chemotherapy and radiation is just as effective, while allowing patients to keep their bladder and maintain function. “This is a big deal. No one wants their bladder removed,” said Craig Stevens, M.D., Ph.D., chairman,
cancer Cancer Discovery Immunotherapies

Discovery Could Lead to Higher Response Rates for Bladder Cancer Patients Treated with Immunotherapy

Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint inhibitors, which enable the immune system to attack tumors. In a study published in August in Nature Communications, the Mount Sinai team reported that stromal cells, a subset of connective tissue cells
Surgery

Robotic Surgery as Effective as Open Surgery for Bladder Cancer

Robotic surgery is as effective as traditional open surgery in treating bladder cancer, according to a landmark study published in the journal Lancet. Three Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study. First author is Dipen Parekh, MD, of the University of Miami. Loyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo robotic
cancer Cancer Discovery

Simultaneous Chemotherapy and Immunotherapy May Be Better for Some Metastatic Bladder Cancer Patients

Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology. Though chemotherapy and immunotherapy have become standard options for the treatment of metastatic bladder
cancer Cancer Discovery

Gene-Based Test for Urine Detects, Monitors Bladder Cancer

Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers. UroSEEK uses urine samples to seek out mutations in 11 genes or the presence of abnormal numbers of chromosomes that would indicate the presence of DNA associated with bladder cancer or upper tract urothelial cancer (UTUC). The researchers said the test, when combined with cytology,
cancer Cancer Discovery

Q&A with Heat Biologics’ Founder and CEO Jeffrey Wolf on T Cell Stimulating Cancer Immunotherapies

Immuno-oncology, a field of fast advancing science that activates a patient’s own immune system against cancer, holds great promise.  A number of companies in the field are developing treatment platforms, many of which are patient-specific (autologous) and therefore costly. Heat Biologics’ ImPACT (Immune Pan-Antigen Cytotoxic Therapy) is fully allogeneic, off-the-shelf and cost-efficient, offering the potential to enhance patients’ natural immune response against certain cancers. ImPACT therapy transforms living allogeneic cells